Mounjaro comparison: how does it stand against other weight-loss medicines?

How does Mounjaro's mechanism actually differ from semaglutide?

Most GLP-1 medicines work by mimicking a single gut hormone (GLP-1) that signals fullness, slows how quickly food leaves the stomach, and nudges the pancreas to release insulin when blood sugar rises. Mounjaro does all of that, and adds activation of the GIP receptor as well. GIP is a second gut hormone involved in appetite regulation and fat metabolism.

That dual action is not just a marketing claim. The prescribing information and the NHS medicines page for tirzepatide both describe the GIP-plus-GLP-1 profile as clinically distinct. Whether that second pathway translates into meaningfully better outcomes for a specific person depends on their biology, which is exactly why a prescriber's assessment matters more than a comparison table.

Wegovy (semaglutide 2.4mg injection) works via GLP-1 only. So does the newly approved Wegovy tablet (25mg oral semaglutide), which the MHRA licensed in June 2026 as the first oral GLP-1 medicine for weight management in the UK. Ozempic is also semaglutide but is licensed for type 2 diabetes, it is not a weight-loss medicine and should not be used as one. If you are browsing a Mounjaro comparison website and see Ozempic listed as a weight-loss option, that is a red flag worth noting.

What does the head-to-head trial evidence say?

Direct comparisons between tirzepatide and semaglutide were, until recently, limited to indirect analysis. SURMOUNT-5 changed that. This open-label randomised trial enrolled 751 adults with obesity and no diabetes, ran for 72 weeks, and compared tirzepatide against semaglutide 2.4mg head-to-head. Tirzepatide produced greater average weight reduction. The results, referenced in NICE's appraisal of tirzepatide (TA1026), are the most rigorous direct evidence available for a UK Mounjaro comparison.

A few context points that any honest Mounjaro comparison should mention. First, the 7.2mg Wegovy pen (approved by the MHRA in April 2026) narrows the gap; trials showed roughly 20.7% average weight loss over 72 weeks at that higher maintenance dose. Second, averages obscure individual variation. Some people respond strongly to semaglutide and moderately to tirzepatide, and vice versa. Third, side-effect tolerability and medical history can shift the clinical choice entirely, regardless of what the group averages show.

If you are comparing purely on trial outcomes, tirzepatide currently holds the edge in head-to-head evidence. If you are comparing on practical factors like how and when you take it, the picture is more nuanced, and that nuance is where a prescriber's input becomes indispensable.

Does cost belong in a Mounjaro comparison?

Honestly, yes, though perhaps not in the way most comparison sites present it. Eli Lilly raised Mounjaro's UK list price from 1 September 2025; the highest dose's list price rose from around £122 to around £330 per four-week pen, and typical private prices since then range roughly £149–£375 a month depending on dose and provider. Wegovy sits in a similar bracket at higher doses.

What matters more than the headline number is what it includes. A quoted price that excludes the consultation, the prescription, clinical review at repeat, and aftercare looks lower until you add those back in. Our Mounjaro price comparison guide covers that breakdown in detail. For now, the short version: price is a reasonable factor to weigh, but it is the wrong primary lens for a prescription medicine. The more important question is whether you are getting genuine supply-chain medicine reviewed by a real clinician.

If you are wondering where compare-the-market-style Mounjaro tools get their figures, they typically draw from list prices or current promotions, neither of which tells you much about the clinical or safety picture. We understand why the temptation to shop around exists; private medicine is expensive and the costs are real. That frustration is legitimate. But for a treatment this significant, the service surrounding the medicine is as important as the price of the pen.

Which medicine is right for you?

No comparison page can answer that, including this one. The relevant variables include your current BMI, any existing health conditions (and which ones, specifically), medications you already take, whether you can manage a weekly injection or would prefer a daily tablet, and how you have responded to previous weight-management attempts. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea; lower thresholds apply for some ethnic backgrounds under UK guidance.

For a fuller picture of tirzepatide on its own terms, our tirzepatide overview covers the licensed indications, dose schedule and trial evidence in detail. The Mounjaro information page focuses on the pen itself, storage, injection technique, and what to expect week by week. And if you want to read about the company behind the medicine, the Mounjaro manufacturer page covers Eli Lilly's UK authorisation and supply chain.

A consultation with one of our prescribers is the practical next step. They will review your medical history, current medications, and goals, and recommend the option that fits, or explain why neither is appropriate right now. There is no obligation and no charge for the consultation itself.